▶ 調査レポート

癌診断の世界市場2020-2030:用途別(血液癌、大腸癌[CRC]、腎癌、肝臓癌、肺癌、卵巣癌、膵癌、前立腺癌)、方法別

• 英文タイトル:Cancer Diagnostics Market (By Application - Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer; By Method - Tumor Biomarker Tests (Prostate Specific Antigen Tests, Circulating Tumor Cells (CTC) Tests, Alpha-Fetoprotein (AFP) Tests, CA 19-9 Tests, CA 125 Tests, EGFR Mutation Tests, HER2 Tests, Carcinoembryonic Antigen (CEA) Tests, BRCA Tests, KRAS Mutation Tests, and Anaplastic Lymphoma Kinase (ALK) Tests), Imaging (Magnetic Resonance Imaging (MRI) Scan, Positron Emission Tomography (PET) Scan, Computed Tomography (CT) Scan, and Mammography), Endoscopy (Colonoscopy, Sigmoidoscopy, Bronchoscopy, and Colposcopy) , Biopsy(Bone Marrow Biopsy, Needle Biopsy, Endoscopic Biopsy)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Transparency Market Researchが調査・発行した産業分析レポートです。癌診断の世界市場2020-2030:用途別(血液癌、大腸癌[CRC]、腎癌、肝臓癌、肺癌、卵巣癌、膵癌、前立腺癌)、方法別 / Cancer Diagnostics Market (By Application - Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer; By Method - Tumor Biomarker Tests (Prostate Specific Antigen Tests, Circulating Tumor Cells (CTC) Tests, Alpha-Fetoprotein (AFP) Tests, CA 19-9 Tests, CA 125 Tests, EGFR Mutation Tests, HER2 Tests, Carcinoembryonic Antigen (CEA) Tests, BRCA Tests, KRAS Mutation Tests, and Anaplastic Lymphoma Kinase (ALK) Tests), Imaging (Magnetic Resonance Imaging (MRI) Scan, Positron Emission Tomography (PET) Scan, Computed Tomography (CT) Scan, and Mammography), Endoscopy (Colonoscopy, Sigmoidoscopy, Bronchoscopy, and Colposcopy) , Biopsy(Bone Marrow Biopsy, Needle Biopsy, Endoscopic Biopsy)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 / MRC20A41資料のイメージです。• レポートコード:MRC20A41
• 出版社/出版日:Transparency Market Research / 2020年10月30日
• レポート形態:英文、PDF、124ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥602,680 (USD5,795)▷ お問い合わせ
  Multi User¥914,680 (USD8,795)▷ お問い合わせ
  Corporate License¥1,226,680 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、癌診断の世界市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、方法別(生検、内視鏡検査、イメージング、腫瘍マーカー検査、フェニトイン、その他)分析、用途別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)分析、競争状況などを掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・癌診断の世界市場規模:方法別(生検、内視鏡検査、イメージング、腫瘍マーカー検査、フェニトイン、その他)
・癌診断の世界市場規模:用途別
・癌診断の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)
・競争状況

Global Cancer Diagnostics Market – Scope of Report

TMR’s report on the global cancer diagnostics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global cancer diagnostics market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global cancer diagnostics market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global cancer diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global cancer diagnostics market.

The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global cancer diagnostics market that have been profiled in this report.

Key Questions Answered in Global Cancer Diagnostics Market Report

What is the scope of growth of product companies in the global cancer diagnostics market?
What will be the Y-o-Y growth of the global cancer diagnostics market between 2019 and 2027?
What is the influence of changing trends in technologies on the global cancer diagnostics market?
Will North America continue to be the most profitable market for cancer diagnostics providers?
Which factors are anticipated to hamper the growth of the global cancer diagnostics market during the forecast period?
Which are the leading companies in the global cancer diagnostics market?
Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global cancer diagnostics market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global cancer diagnostics market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the cancer diagnostics market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the cancer diagnostics market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global cancer diagnostics market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global cancer diagnostics market more reliably and accurately.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objective

1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Diagnostics Market

4. Market Overview

4.1. Introduction

4.1.1. Type Definition

4.1.2. Industry Evolution / Development

4.2. Overview

4.3. Market Dynamic

4.3.1. Driver

4.3.2. Restraint

4.3.3. Opportunitie

4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Regulatory Scenario and Reimbursement

5.2. Cancer Epidemiology

5.3. List of active market participants (suppliers/distributors/manufacturers/vendors)

6. Global Cancer Diagnostics Market Analysis and Forecast, by Method

6.1. Introduction & Definition

6.1.1. Key Findings / Development

6.2. Global Cancer Diagnostics Market Value Forecast, by Method, 2017–2027

6.2.1. Biopsy

6.2.1.1. Bone Marrow Biopsy

6.2.1.2. Needle Biopsy

6.2.1.3. Endoscopic Biopsy

6.2.2. Endoscopy

6.2.2.1. Bronchoscopy

6.2.2.2. Colonoscopy

6.2.2.3. Sigmoidoscopy

6.2.2.4. Colposcopy

6.2.2.5. Other

6.2.3. Imaging

6.2.3.1. MRI Scan

6.2.3.2. PET Scan

6.2.3.3. CT Scan

6.2.3.4. Mammography

6.2.3.5. Ultrasound

6.2.4. Tumor Biomarker Test

6.2.4.1. PSA Test

6.2.4.2. CTC Test

6.2.4.3. AFP Test

6.2.4.4. CA 19-9

6.2.4.5. CA 125

6.2.4.6. EGFR

6.2.4.7. HER2

6.2.4.8. CEA

6.2.4.9. BRCA

6.2.4.10. KRA

6.2.4.11. ALK

6.3. Global Cancer Diagnostics Market Attractiveness, by Method

7. Global Cancer Diagnostics Market Analysis and Forecast, by Application

7.1. Introduction & Definition

7.1.1. Key Findings / Development

7.2. Global Cancer Diagnostics Market Value Forecast, by Application, 2017–2027

7.2.1. Blood Cancer

7.2.2. Breast Cancer

7.2.3. Colorectal Cancer

7.2.4. Kidney Cancer

7.2.5. Liver Cancer

7.2.6. Lung Cancer

7.2.7. Ovarian Cancer

7.2.8. Pancreatic Cancer

7.2.9. Prostate Cancer

7.3. Global Cancer Diagnostics Market Attractiveness, by Application

8. Global Cancer Diagnostics Market Analysis and Forecast, by Region

8.1. Key Finding

8.2. Global Cancer Diagnostics Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. North America Cancer Diagnostics Market Attractiveness, by Region

9. North America Cancer Diagnostics Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Finding

9.2. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

9.2.1. Biopsy

9.2.1.1. Bone Marrow Biopsy

9.2.1.2. Needle Biopsy

9.2.1.3. Endoscopic Biopsy

9.2.2. Endoscopy

9.2.2.1. Bronchoscopy

9.2.2.2. Colonoscopy

9.2.2.3. Sigmoidoscopy

9.2.2.4. Colposcopy

9.2.2.5. Other

9.2.3. Imaging

9.2.3.1. MRI Scan

9.2.3.2. PET Scan

9.2.3.3. CT Scan

9.2.3.4. Mammography

9.2.3.5. Ultrasound

9.2.4. Tumor Biomarker Test

9.2.4.1. PSA Test

9.2.4.2. CTC Test

9.2.4.3. AFP Test

9.2.4.4. CA 19-9

9.2.4.5. CA 125

9.2.4.6. EGFR

9.2.4.7. HER2

9.2.4.8. CEA

9.2.4.9. BRCA

9.2.4.10. KRA

9.2.4.11. ALK

9.3. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

9.3.1. Blood Cancer

9.3.2. Breast Cancer

9.3.3. Colorectal Cancer

9.3.4. Kidney Cancer

9.3.5. Liver Cancer

9.3.6. Lung Cancer

9.3.7. Ovarian Cancer

9.3.8. Pancreatic Cancer

9.3.9. Prostate Cancer

9.4. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Cancer Diagnostics Market Attractiveness Analysi

9.5.1. By Method

9.5.2. By Application

9.5.3. By Country

10. Europe Cancer Diagnostics Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Finding

10.2. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

10.2.1. Biopsy

10.2.1.1. Bone Marrow Biopsy

10.2.1.2. Needle Biopsy

10.2.1.3. Endoscopic Biopsy

10.2.2. Endoscopy

10.2.2.1. Bronchoscopy

10.2.2.2. Colonoscopy

10.2.2.3. Sigmoidoscopy

10.2.2.4. Colposcopy

10.2.2.5. Other

10.2.3. Imaging

10.2.3.1. MRI Scan

10.2.3.2. PET Scan

10.2.3.3. CT Scan

10.2.3.4. Mammography

10.2.3.5. Ultrasound

10.2.4. Tumor Biomarker Test

10.2.4.1. PSA Test

10.2.4.2. CTC Test

10.2.4.3. AFP Test

10.2.4.4. CA 19-9

10.2.4.5. CA 125

10.2.4.6. EGFR

10.2.4.7. HER2

10.2.4.8. CEA

10.2.4.9. BRCA

10.2.4.10. KRA

10.2.4.11. ALK

10.3. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

10.3.1. Blood Cancer

10.3.2. Breast Cancer

10.3.3. Colorectal Cancer

10.3.4. Kidney Cancer

10.3.5. Liver Cancer

10.3.6. Lung Cancer

10.3.7. Ovarian Cancer

10.3.8. Pancreatic Cancer

10.3.9. Prostate Cancer

10.4. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Cancer Diagnostics Market Attractiveness Analysi

10.5.1. By Method

10.5.2. By Application

10.5.3. By Country/Sub-region

11. Asia Pacific Cancer Diagnostics Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Finding

11.2. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

11.2.1. Biopsy

11.2.1.1. Bone Marrow Biopsy

11.2.1.2. Needle Biopsy

11.2.1.3. Endoscopic Biopsy

11.2.2. Endoscopy

11.2.2.1. Bronchoscopy

11.2.2.2. Colonoscopy

11.2.2.3. Sigmoidoscopy

11.2.2.4. Colposcopy

11.2.2.5. Other

11.2.3. Imaging

11.2.3.1. MRI Scan

11.2.3.2. PET Scan

11.2.3.3. CT Scan

11.2.3.4. Mammography

11.2.3.5. Ultrasound

11.2.4. Tumor Biomarker Test

11.2.4.1. PSA Test

11.2.4.2. CTC Test

11.2.4.3. AFP Test

11.2.4.4. CA 19-9

11.2.4.5. CA 125

11.2.4.6. EGFR

11.2.4.7. HER2

11.2.4.8. CEA

11.2.4.9. BRCA

11.2.4.10. KRA

11.2.4.11. ALK

11.3. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

11.3.1. Blood Cancer

11.3.2. Breast Cancer

11.3.3. Colorectal Cancer

11.3.4. Kidney Cancer

11.3.5. Liver Cancer

11.3.6. Lung Cancer

11.3.7. Ovarian Cancer

11.3.8. Pancreatic Cancer

11.3.9. Prostate Cancer

11.4. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Cancer Diagnostics Market Attractiveness Analysi

11.5.1. By Method

11.5.2. By Application

11.5.3. By Country/Sub-region

12. Latin America Cancer Diagnostics Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Finding

12.2. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

12.2.1. Biopsy

12.2.1.1. Bone Marrow Biopsy

12.2.1.2. Needle Biopsy

12.2.1.3. Endoscopic Biopsy

12.2.2. Endoscopy

12.2.2.1. Bronchoscopy

12.2.2.2. Colonoscopy

12.2.2.3. Sigmoidoscopy

12.2.2.4. Colposcopy

12.2.2.5. Other

12.2.3. Imaging

12.2.3.1. MRI Scan

12.2.3.2. PET Scan

12.2.3.3. CT Scan

12.2.3.4. Mammography

12.2.3.5. Ultrasound

12.2.4. Tumor Biomarker Test

12.2.4.1. PSA Test

12.2.4.2. CTC Test

12.2.4.3. AFP Test

12.2.4.4. CA 19-9

12.2.4.5. CA 125

12.2.4.6. EGFR

12.2.4.7. HER2

12.2.4.8. CEA

12.2.4.9. BRCA

12.2.4.10. KRA

12.2.4.11. ALK

12.3. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

12.3.1. Blood Cancer

12.3.2. Breast Cancer

12.3.3. Colorectal Cancer

12.3.4. Kidney Cancer

12.3.5. Liver Cancer

12.3.6. Lung Cancer

12.3.7. Ovarian Cancer

12.3.8. Pancreatic Cancer

12.3.9. Prostate Cancer

12.4. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America Latin America

12.5. Latin America Cancer Diagnostics Market Attractiveness Analysi

12.5.1. By Method

12.5.2. By Application

12.5.3. By Country/Sub-region

13. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Finding

13.2. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

13.2.1. Biopsy

13.2.1.1. Bone Marrow Biopsy

13.2.1.2. Needle Biopsy

13.2.1.3. Endoscopic Biopsy

13.2.2. Endoscopy

13.2.2.1. Bronchoscopy

13.2.2.2. Colonoscopy

13.2.2.3. Sigmoidoscopy

13.2.2.4. Colposcopy

13.2.2.5. Other

13.2.3. Imaging

13.2.3.1. MRI Scan

13.2.3.2. PET Scan

13.2.3.3. CT Scan

13.2.3.4. Mammography

13.2.3.5. Ultrasound

13.2.4. Tumor Biomarker Test

13.2.4.1. PSA Test

13.2.4.2. CTC Test

13.2.4.3. AFP Test

13.2.4.4. CA 19-9

13.2.4.5. CA 125

13.2.4.6. EGFR

13.2.4.7. HER2

13.2.4.8. CEA

13.2.4.9. BRCA

13.2.4.10. KRA

13.2.4.11. ALK

13.3. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

13.3.1. Blood Cancer

13.3.2. Breast Cancer

13.3.3. Colorectal Cancer

13.3.4. Kidney Cancer

13.3.5. Liver Cancer

13.3.6. Lung Cancer

13.3.7. Ovarian Cancer

13.3.8. Pancreatic Cancer

13.3.9. Prostate Cancer

13.4. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC Countrie

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Cancer Diagnostics Market Attractiveness Analysi

13.5.1. By Method

13.5.2. By Application

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (by Tier and Size of companies)

14.2. Market Share / Position Analysis, by Company, 2018

14.3. Competitive Business Strategie

14.4. Company Profile

14.4.1. Abbott

14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.1.2. Growth Strategie

14.4.1.3. SWOT Analysi

14.4.2. Ambry Genetics

14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.2.2. Growth Strategie

14.4.2.3. SWOT Analysi

14.4.3. AstraZeneca plc

14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.3.2. Growth Strategie

14.4.3.3. SWOT Analysi

14.4.4. bioMeriux SA

14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.4.2. Growth Strategie

14.4.4.3. SWOT Analysi

14.4.5. Eli Lilly and Company

14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.5.2. Growth Strategie

14.4.5.3. SWOT Analysi

14.4.6. Genoptix, Inc

14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.6.2. Growth Strategie

14.4.6.3. SWOT Analysi

14.4.7. GlaxoSmithKline plc

14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.7.2. Growth Strategie

14.4.7.3. SWOT Analysi

14.4.8. F. Hoffmann-La Roche Ltd

14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.8.2. Growth Strategie

14.4.8.3. SWOT Analysi

14.4.9. Pfizer, Inc

14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.4.9.2. Growth Strategie

14.4.9.3. SWOT Analysis

List of Table

Table 1List of Abbreviation

Table 2Market Snapshot: Global Cancer Diagnostics Market

Table 3List of Cancer Risk Factors

Table 4Estimated Incidence, 1 year, 2 years and 5 years survival

Table 5Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 6Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 7Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 8Summary of Type of Diagnostics Test in the U.S.

Table 9Event Impact Analysis: Global Cancer Diagnostics Market, 2017-2027

Table 10Global Cancer Diagnostics Market Revenue, by Method, 2017-2027 (USD) Million

Table 11Global Cancer Diagnostics Market Revenue, by Application, 2017-2027 (USD) Million

Table 12Global Cancer Diagnostics Market Revenue, by Geography, 2017-2027 (USD) Million